HENDERSON, Nev., March 25, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture-Seq™ technology.

“As we reported previously, Volition has developed a new liquid biopsy method, Capture-Seq™, which enriches and purifies plasma samples resulting in virtually pure circulating tumor DNA (ctDNA) samples for analysis.

“We are now releasing the data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and are extremely encouraged by the results, particularly in early-stage cancer detection.